Stonepine Capital Management, LLC Gamida Cell Ltd. Transaction History

Stonepine Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.85 - $1.87 $6.77 Million - $14.9 Million	7,965,865 New	7,965,865 $8.2 Billion
Q2 2023 Aug 11, 2023	BUY	$0.73 - $2.37 $1.1 Million - $3.56 Million	1,500,000 New	1,500,000 $2.9 Million
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $3.79 Million - $7.69 Million	-1,724,201 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.85 - $6.44 $4.93 Million - $8.25 Million	1,280,694 Added 288.77%	1,724,201 $6.76 Million
Q2 2021 Aug 16, 2021	BUY	$5.85 - $8.33 $1.16 Million - $1.66 Million	198,992 Added 81.38%	443,507 $2.84 Million

Q1 2021 May 14, 2021	SELL	$7.8 - $12.43 $1.05 Million - $1.68 Million	-134,955 Reduced 35.56%	244,515 $1.98 Million
Q4 2020 Feb 12, 2021	BUY	$4.07 - $11.0 $1.54 Million - $4.17 Million	379,470 New	379,470 $3.18 Million

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.